Eva L Feldman
James W Albers Distinguished University Professor of Neurology
Russell N DeJong Professor of Neurology
Professor of Neurology
Section Head
Co-Division Chief Neuromuscular
Neurology
109 Zina Pitcher Place, 5017 AAT-BSRB
Ann Arbor, MI 48109
[email protected]

Available to mentor

Eva L Feldman
Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • About

    I am the Russell N. DeJong Professor of Neurology, Director of the NeuroNetwork for Emerging Therapies, and Director of the University of Michigan Neuropathy Center and ALS Center of Excellence. I am annually listed in Best Doctors in America, a Past President of the Peripheral Nerve Society and American Neurological Association (ANA), a member of the National Academy of Medicine and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. As of summer 2020, I am Chair of the Neurology and Psychiatry Section of the National Academy of Medicine. My work is internationally recognized and published in >500articles and 70 book chapters (Google Scholar h-index = 109), with over 45,000 citations. I have been continuously NIH funded since 1989, and I oversee an established laboratory of 25 exceptional scientists. My laboratory develops novel cellular, gene, and growth factor therapies for neurologic disorders. I conducted pioneering studies on the pathogenesis of neuropathy in metabolic diseases, leveraging in vitro and in vivo models, clinical specimens, and multiple omics-based approaches, and identified dyslipidemia during diabetes as a key driver of nervous system damage, leading to new clinical patient care guidelines by the American Diabetes Association. I also developed a clinical tool to diagnose diabetic neuropathy that is used worldwide and in multiple NIH clinical trials. I have a strong track record of successful collaborations, and am a pioneer in directly transforming basic research into advances in clinical treatment. I led the first and only FDA-approved Phase 1 and 2 trials of direct spinal cord stem cell transplantation in amyotrophic lateral sclerosis (ALS). We are planning a Phase 3 trial and developing a similar cellular therapy for Alzheimer’s disease. I established an ALS biorepository to facilitate studies to increase our understanding of disease pathogenesis, and uncovered epigenetic, metabolomic, and immunological mechanisms representing potential biomarkers and therapeutic targets, and further identified environmental toxins as risk factors. I have mentored over 100 postdoctoral and clinical fellows and 9 neuroscience graduate students, and I was PI of the University of Michigan T32 NIH/NINDS Training in Clinical and Basic Neuroscience for ~2 decades. Thus, I have a long-standing history of effective biomedical research, translational clinical applications, leadership, and career development and mentoring.

    Links
    Qualifications
    • Fellow
      University of Michigan, Neuromuscular Disorders, 1998
    • Residency
      Johns Hopkins Hospital, Neurology, 1987
    • Chief Resident
      Johns Hopkins, Neurology, 1987
    • Internship
      William Beaumont Hospital, Internal Medicine, 1984
    • MD, Medicine
      University of Michigan Medical School, Ann Arbor, 1983
    • PhD, Neuroscience
      University of Michigan Medical School, Ann Arbor, 1979
    • MS, Zoology
      University of Notre Dame, South Bend, 1975
    • BA, Biology and Chemistry
      Earlham College, Richmond, 1973
    Center Memberships
    • Center Member
      Center for Cell Plasticity and Organ Design
    • Center Member
      Biosciences Initiative
    • Center Member
      Caswell Diabetes Institute
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      Taubman Institute
    Research Overview

    Diabetes and obesity complications
    Peripheral neuropathy
    Cognitive decline
    Alzheimer's disease
    Amyotrophic lateral sclerosis (ALS)

    Recent Publications See All Publications
    • Journal Article
      Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome.
      Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, Feldman EL. Ann Neurol, 1990 Mar; 27 (3): 304 - 315. DOI:10.1002/ana.410270313
      PMID: 2327738
    • Journal Article
      Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.
      Pestronk A, Chaudhry V, Feldman EL, Griffin JW, Cornblath DR, Denys EH, Glasberg M, Kuncl RW, Olney RK, Yee WC. Ann Neurol, 1990 Mar; 27 (3): 316 - 326. DOI:10.1002/ana.410270314
      PMID: 2327739
    • Journal Article
      Culture versus biology: children's attitudes toward thinness and fatness.
      Feldman W, Feldman E, Goodman JT. Pediatrics, 1988 Feb; 81 (2): 190 - 194.
      PMID: 3422404
    • Journal Article
      Prospective study of school injuries: incidence, types, related factors and initial management.
      Feldman W, Woodward CA, Hodgson C, Harsanyi Z, Milner R, Feldman E. Can Med Assoc J, 1983 Dec 15; 129 (12): 1279 - 1283.
      PMID: 6652594
    • Journal Article
      Studies on the localization of newly added membrane in growing neurites.
      Feldman EL, Axelrod D, Schwartz M, Heacock AM, Agranoff BW. J Neurobiol, 1981 Nov; 12 (6): 591 - 598. DOI:10.1002/neu.480120607
      PMID: 7310397
    • Journal Article
      Histological localization of binding sites of alpha-bungarotoxin and of antibodies specific to acetylcholine receptor in goldfish optic nerve and tectum.
      Schwartz M, Axelrod D, Feldman EL, Agranoff BW. Brain Res, 1980 Jul 21; 194 (1): 171 - 180. DOI:10.1016/0006-8993(80)91326-8
      PMID: 7378835
    • Journal Article
      The retina as a biochemical model of central nervous system regeneration.
      Agranoff BW, Feldman EL, Heacock AM, Schwartz M. Neurochem Int, 1980 1C: 487 - 500. DOI:10.1016/0197-0186(80)90082-0
      PMID: 20487757
    • Journal Article
      Avocational exposure associations with ALS risk, survival, and phenotype: A Michigan-based case-control study.
      Goutman SA, Boss J, Jang DG, Piecuch C, Farid H, Batra M, Mukherjee B, Feldman EL, Batterman SA. J Neurol Sci, 2024 Jan 23; 457: 122899 DOI:10.1016/j.jns.2024.122899
      PMID: 38278093
    Featured News & Stories
    Department News
    A Role for Neurologists in Diabetic Peripheral Neuropathy
    A Role for Neurologists at the University of Michigan in Diabetic Peripheral Neuropathy.
    Department News
    Environmental toxin exposure may predict ALS risk
    Experts say environmental toxin exposure may predict ALS risks.
    Department News
    Drawing a tube of blood could assess ALS risk from environmental toxin exposure
    Drawing a tube of blood could assess ALS risk from environmental toxin exposure, experts say.
    Department News
    Study: Spinal cord stimulation offers unmatched pain relief for diabetic neuropathy
    Study: Spinal Cord Stimulation Offers Unmatched Pain Relief for Diabetic Neuropathy
    Department News
    The mystery of why some people develop ALS
    University of Michigan experts explore the mystery of why some people develop ALS.
    Department News
    Duration of T2D negatively linked to mean cortical thickness
    Duration of T2D negatively linked to mean cortical thickness